Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines

Abstract: Our goal was to compare the recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2014 (KMAP-BP 2014) with other recently published guidelines for the treatment of bipolar disorder. We reviewed a total of four recently published global treatment guidelines and compared each treatment recommendation of the KMAP-BP 2014 with those in other guidelines. For the initial treatment of mania, there were no significant differences across treatment guidelines. All recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or the combination of an MS with an AAP as a first-line treatment strategy for mania. However, the KMAP-BP 2014 did not prefer monotherapy with MS or AAP for dysphoric/psychotic mania. Aripiprazole, olanzapine, quetiapine, and risperidone were the first-line AAPs in nearly all of the phases of bipolar disorder across the guidelines. Most guidelines advocated newer AAPs as first-line treatment options in all phases, and lamotrigine in depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. As research evidence accumulated over time, recommendations of newer AAPs—such as asenapine, paliperidone, lurasidone, and long-acting injectable risperidone—became prominent. This comparison identifies that the treatment recommendations of the KMAP-BP 2014 are similar to those of other treatment guidelines and reflect current changes in prescription patterns for bipolar disorder based on accumulated research data. Further studies are needed to address several issues identified in our review.

Keywords: bipolar disorder, pharmacotherapy, treatment algorithm, guideline comparison, KMAP-2014

Introduction
Bipolar disorder is characterized by diverse symptoms such as manic, depressive and mixed symptoms, and by recurrent patterns that cause challenges for treatment. Beginning in the 1990s, medical practice has shifted from experience-based to more evidence-based approaches. This trend has contributed to the development of treatment algorithms or clinical practice guidelines in psychiatric fields, including several treatment algorithms for bipolar disorder.

However, the medical situation differs across countries; at times, the use of treatment guidelines may be constrained by cultural differences in clinical environments and medical situations, or by the culture-specific needs of clinicians and patients.

In Korea, a medication algorithm project (Korean Medication Algorithm Project for Bipolar Disorder, KMAP-BP) was initiated in 2001 and KMAP-BP was published in 2002 (KMAP-BP 2002), with its feasibility confirmed. Revised versions of KMAP-BP were released in 2006 and 2010. However, newer atypical antipsychotics (AAPs) and
mood stabilizers (MSs) were introduced for the treatment of bipolar disorder, and the mood-stabilizing effect of AAPs was demonstrated.

To reflect the current changes in treatment strategies for bipolar disorder, the previous algorithm was revised, resulting in the publication of the KMAP-BP in 2014 (KMAP-BP 2014). In the current article, we compare the recommendations of KMAP-BP 2014 with those of other recently published global treatment guidelines (British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder [BAP], Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder [CANMAT], National Institute for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder [NICE], The World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder [WFSBP]).

By identifying similarities and differences across treatment guidelines, our goal was to identify potential deficiencies in KMAP-BP 2014 that would require additional attention or supplementary information, enhancing the usefulness of the KMAP-BP 2014 guidelines to clinical practice.

Treatment guidelines as comparison targets

British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder

The British Association for Psychopharmacology constructed a set of guidelines based on the American Psychiatric Association Practice Guidelines for Bipolar Disorder, revised in 2002. The BAP adapted the American guidelines with the aim of guiding clinical decision-making in Britain and published these revisions in 2009 as the British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder 2009 (BAP 2009). BAP 2009 consists of a list of clinical guidelines (Part 1) and their key points and supporting evidence (Part 2). It provides an evaluation of the supporting evidence; evidence is categorized as ranging from Category I (the most powerful evidence) to Category IV (the weakest). In addition, the strength of each recommendation is categorized from Grade A (the strongest recommendation) to Grade D (the weakest). The guidelines reflect the consensus of experts and a wide range of feedback. The BAP 2009 also provides basic information to patients and caregivers about diagnosis and treatment (Table 1).

Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder

The Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments collaborated to publish evidence-based clinical guidelines for bipolar disorder in 1997. The guidelines were subsequently revised in 2005, 2007, 2009, and 2013 to reflect new evidence. CANMAT is a set of evidence-based treatment guidelines reflecting a comprehensive literature review. The treatment recommendations are categorized into four levels based on the strength of supporting evidence (Table 1).

National Institute for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder (NICE clinical guideline 185)

NICE guideline has published numerous treatment guidelines, and among them is a set of guidelines for bipolar disorder that are based on a comprehensive literature review. The first edition of the NICE guidelines for bipolar disorder was published in 2006, with a subsequent revision in 2014. Because the NICE guidelines are intended to serve a group of professionals working in various psychiatric fields, they provide relatively simple recommendations pertaining to the

Table 1 Summary of recent bipolar disorder treatment guidelines

<table>
<thead>
<tr>
<th>Organization</th>
<th>Publication date</th>
<th>Audience</th>
<th>Methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>KMAP-BP</td>
<td>2014</td>
<td>Psychiatrists</td>
<td>Expert consensus</td>
</tr>
<tr>
<td>BAP</td>
<td>2009</td>
<td>Psychiatrists</td>
<td>Evidence-based</td>
</tr>
<tr>
<td>CANMAT</td>
<td>2013</td>
<td>Primary care physicians</td>
<td></td>
</tr>
<tr>
<td>NICE</td>
<td>2014</td>
<td>Psychiatrists</td>
<td></td>
</tr>
<tr>
<td>WFSBP</td>
<td>2009 (acute mania, mixed, rapid cycling)</td>
<td>Psychiatrists</td>
<td>Evidence-based</td>
</tr>
<tr>
<td></td>
<td>2013 (maintenance)</td>
<td>Primary care physicians</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2010 (acute depression)</td>
<td>Primary care physicians</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: KMAP-BP, Korean Medication Algorithm Project for Bipolar Disorder; BAP, British Association for Psychopharmacology; CANMAT, Canadian Network for Mood and Anxiety Treatments; NICE, National Institute for Health and Clinical Excellence; WFSBP, World Federation of Societies of Biological Psychiatry.
level of diagnosis and treatment, and do not clearly define the strength of evidence or clearly differentiate among treatment recommendations (Table 1).

The World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder

The World Federation of Societies of Biological Psychiatry developed guidelines for bipolar disorder based on a comprehensive literature review. Guidelines addressing the depressive episode were published in 2002, followed by guidelines for the manic episode in 2003, and for maintenance therapy in 2004. Revisions were released in 2009 (manic episode), 2010 (depressive episode), and 2013 (maintenance therapy) to reflect new evidence. Treatment recommendations are categorized according to five levels depending on the strength of the supporting evidence (Table 1).

Development of the KMAP-BP 2014

The KMAP-BP 2014 guidelines reflect expert consensus. This revised edition of the Korean Medication Algorithm for Bipolar Disorder used the same framework as the KMAP-BP 2010 (the second revision of the algorithm). The survey questionnaire that was used for the KMAP-BP 2014 included many of the same questions used in the KMAP-BP 2010 but also contained several modifications. The 2014 edition featured newly added questions regarding treatment strategies for manic/hypomanic episodes, mixed/psychotic mania, depressive episodes, rapid cycling, and maintenance. It also added new questions pertaining to safety and compliance issues, and to strategies for special situations. The final 56-item questionnaire consisted of seven parts. The nine-point scale from the RAND Corporation was used to evaluate the adequacy of each treatment option. The survey was sent to a review panel of 110 Korean psychiatrists with extensive clinical experience and academic achievements in bipolar disorder. Reflecting a variety of medical contexts, the reviewers’ affiliations included university hospitals, general hospitals, mental hospitals, and private psychiatric clinics. Seventy-three out of the 110 reviewers worked at university hospitals, 24 at general hospitals/mental hospitals, and 13 in private clinics. Sixty-four out of the 110 (58.21%) responded to the survey questionnaire; of these, 42 were at university hospitals, 19 at general hospitals/mental hospitals, and four in private psychiatric clinics.

By estimating the means and 95% confidence intervals (CIs) for each question item, we classified each treatment opinion into one of three categories based on the lowest CI category: 6.5 or greater for first-line treatment, 3.5–6.5 for second-line treatment, and lower than 3.5 for third-line treatment. If a first-line option was recommended by 50% or more of the experts, it was labeled as a “treatment of choice”. The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board of Yeouido St Mary’s Hospital.

Comparisons of recommendations across treatment guidelines

Acute mania/hypomania

Initial treatment

For acute euphoric/classic mania, MS monotherapy (lithium or valproic acid) and a combination of MS and AAP are preferred as the first-line treatments in KMAP-BP 2014. The combination of MS and AAP is preferred in mixed and psychotic mania, and AAP monotherapy is a first-line treatment strategy in psychotic mania. The treatment strategy for hypomanic episodes is a monotherapy of MS or AAP. In KMAP-BP 2014, the combination of MS and AAP is the treatment of choice in all three types of mania (euphoric, mixed, and psychotic).

These recommendations are in line with the other treatment guidelines. However, other guidelines recommend not only the combination of AAP and MS but also AAP or MS monotherapies as first-line strategies in mixed/psychotic mania.

The WFSBP guidelines recommend valproic acid as the first-line medication; this result seems to reflect concerns regarding the safety of lithium. However, the guidelines advise caution in using valproic acid to treat females because of the risk of polycystic ovarian syndrome.

In the KMAP-BP 2014, lithium and valproic acid are the preferred MS agents; this choice is consistent with the results of other previous guidelines. However, the newly published NICE guidelines do not recommend lithium or valproic acid as first-line treatment strategies in drug-naïve manic patients. This discrepancy is thought to be related to the fact that the NICE guidelines target a group of professionals working in various psychiatric fields, and hence provide relatively simply recommendations for diagnosis and treatment rather than offering the full range of treatments differentiated in accordance with supporting evidence and recommendation strength.

Aripiprazole, olanzapine, quetiapine, and risperidone are the first-line AAPs in euphoric, mixed, and psychotic mania, and risperidone is preferred as the second-line AAP for hypomanic episodes. These recommendations for manic...
episodes are in line with the other treatment guidelines.\textsuperscript{13,14,16} Additionally, CANMAT 2013\textsuperscript{14} recommends monotherapy of ziprasidone (also in WFSBP 2009\textsuperscript{16}), asenapine, and paliperidone, and adjunctive asenapine with MS as first-line treatment strategies for treating euphoric/classic mania. Haloperidol mono- and adjunctive therapy are also primarily recommended in NICE 2014.\textsuperscript{15}

KMAP-BP 2014 and other guidelines recommend AAP therapy for mood stabilization, based on numerous published studies of AAP efficacy in treating manic/hypomanic episodes (Tables 2 and 3).

**Next-step strategy**

In cases of nonresponse or incomplete response to first-line strategies, guidelines recommend switching or adding another first-line agent. KMAP-BP 2014 recommends switching from an MS or AAP to a different agent of the same type.\textsuperscript{12} Additionally, triple combinations such as lithium + two AAPs or lithium + valproic acid + AAP are suggested as next-step interventions in KMAP-BP 2014. Other guidelines are not substantially different, but CANMAT 2013\textsuperscript{14} recommends carbamazepine, which is not a first-line treatment strategy, as a next-step intervention. Additionally, asenapine, paliperidone, and electroconvulsive therapy (ECT) are highly recommended by CANMAT 2013.\textsuperscript{14}

When MS and AAP combination therapy results in incomplete efficacy in treating mixed/psychotic mania, KMAP-BP 2014 recommends changing the specific MS or AAP, or adding another MS or AAP.\textsuperscript{12} However, because the other guidelines do not provide separate recommendations for the treatment of

| Table 2 Treatment of acute euphoric/classic mania across practice guidelines |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Guidelines**              | **First-line treatment**    | **Next-step intervention**  | **Later intervention**       |
| KMAP-BP 2014\textsuperscript{13} | Li, Val, Li or Val + AAP | Li or Val + AAP, Li or Val + | Two AAPs + Li + Val, Li +   |
| BAP 2009\textsuperscript{13}  | Mild: AP or Val or Li (or CBZ) | Li or Val + AP | Val + other AAP             |
| CANMAT 2013\textsuperscript{14} | Li, Val, OLZ, RIS, QTP, QTPXR, ARP, ZIP, ASP, PAL | CBZ, ECT, HP, Li + Val | CPZ, CLZ, OXC, tamoxifen, cariprazine, Li or Val + HP, Li + CBZ, adjunctive tamoxifen |
| NICE 2014\textsuperscript{15} | Without AM: HP, OLZ, QTP, OLZ | Alternative AP or adding Li | ECT                        |
| WFSBP 2009\textsuperscript{16} | Monotherapy with CE I and RG A such as Val, ARP, ZIP, and RIS | Optimize dosage; switch to another first-line agent; in severe mania, consider combination of two first-line agents | Add-on with first-line agent; combination of two first-line agents |

**Abbreviations:** KMAP-BP 2014, Korean Medication Algorithm Project for Bipolar Disorder 2014; BAP 2009, The British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder 2009; CANMAT 2013, Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder 2013; NICE 2014, National Institute for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder 2014; WFSBP 2009, World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder 2009 (treatment of acute mania); Li, lithium; Val, various kinds of valproic acids; AAP, atypical antipsychotic; AP, antipsychotics; CBZ, carbamazepine; iM, intramuscular formulation; BZ, benzodiazepine; eCT, electroconvulsive therapy; CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QTP, quetiapine; QTPXR, quetiapine XR; ARP, aripiprazole; ZiP, ziprasidone; ASP, asenapine; PAL, paliperidone; HP, haloperidol; CPZ, chlorpromazine; OXC, oxcarbazepine; AM, anionic agents; CE, categories of evidence; RG, recommendation of grade.

| Table 3 Treatment of mixed/psychotic mania across practice guidelines |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Guidelines**              | **First-line treatment**    | **Next-step intervention**  | **Later intervention**       |
| KMAP-BP 2014\textsuperscript{12} | Mixed mania: Val or Li + AAP | Li or Val + AAP, Li or Val + | Two AAPs + Li + Val, Li +   |
| BAP 2009\textsuperscript{13}  | Psychotic mania: Val or Li + AAP | Li or Val + AAP | Val + other AAP             |
| CANMAT 2013\textsuperscript{14} | Same as for euphoric mania; AAP in psychotic mania | Same as for euphoric mania | Same as for euphoric mania |
| NICE 2014\textsuperscript{15} | Not mentioned | Same as for euphoric mania | Same as for euphoric mania |
| WFSBP 2009\textsuperscript{16} | Val, AAP (OLZ, ZIP, ARP) | Val, AAP (OLZ, ZIP, ARP) | Val, AAP (OLZ, ZIP, ARP) |

**Abbreviations:** KMAP-BP 2014, Korean Medication Algorithm Project for Bipolar Disorder 2014; BAP 2009, The British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder 2009; CANMAT 2013, Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder 2013; NICE 2014, National Institute for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder 2014; WFSBP 2009, World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder 2009 (treatment of acute mania); Val, various kinds of valproic acids; Li, lithium; AAP, atypical antipsychotic; OLZ, olanzapine; ZIP, ziprasidone; ARP, aripiprazole; RIS, risperidone; CBZ, carbamazepine.
mixed-psychotic mania, direct comparison between KMAP-BP 2014 and the other guidelines is not possible.

In cases of incomplete response to second-line strategies, next-step interventions vary among the guidelines. However, ECT and clozapine are recommended in most guidelines, while chlorpromazine, tamoxifen, and cariprazine are recommended only in CANMAT 201314 (Tables 2 and 3).

**Bipolar depression**

**Initial treatment**

KMAP-BP 2014 divides bipolar depression into categories of mild, moderate, severe, and psychotic.12 MS monotherapy, or AAP in combination with MS or lamotrigine, is the first-line strategy for mild-to-moderate episodes of bipolar depression. In severe depression without psychotic features, MS in combination with AAP or antidepressants (ADs) is preferred. Lamotrigine can be combined with AAP in severe bipolar depression. AAP + MS, AAP + lamotrigine, AAP + AD, AAP + MS + lamotrigine, AAP + AD + MS, and AAP + AD + lamotrigine are first-line treatment strategies for psychotic depression.

Valproic acid, lithium, and lamotrigine are rated as first-line MS treatments for bipolar depression. Preferred AAPs for bipolar depression are quetiapine, aripiprazole, and olanzapine. However, ziprasidone, risperidone, amisulpride, blonanserin, and paliperidone are second-line AAPs. If AD is needed in bipolar depression, bupropion, (es)citalopram, and sertraline are the first-line drugs, and mirtazapine and venlafaxine are other options for severe depression.

The BAP 2009 guidelines13 primarily recommend quetiapine and lamotrigine as monotherapeutic agents for mild-to-moderate bipolar depression, and selective serotonin reuptake inhibitors (SSRIs) are also recommended in combination with MS or AAP. ECT is a first-line treatment strategy for severe bipolar depression. In WFSBP 2010, quetiapine monotherapy, adjunctive quetiapine, an olanzapine–fluoxetine combination, olanzapine, lamotrigine, lamotrigine + lithium, and valproic acid are recommended as first-line strategies.17 CANMAT 201314 contains a wider range of therapeutic recommendations, with lithium, lamotrigine, quetiapine, quetiapine XR, MS + SSRI, olanzapine + SSRI, lithium + valproic acid, and MS + bupropion as first-line treatment strategies. The most recently published guideline, NICE 2014,15 recommends olanzapine + fluoxetine, quetiapine, olanzapine, and lamotrigine for bipolar depression patients who are not taking antimanic agents, depending on the patient’s preferences and previous response to treatment. If a depressive episode develops during lithium therapy, optimization of lithium, olanzapine + fluoxetine, adjunctive quetiapine, adjunctive olanzapine, and adjunctive lamotrigine are first-line strategies.

The KMAP-BP 2014 is in line with the other guidelines regarding the increased preference for AAP without specifying that the recommendation by the other guidelines is restricted to some, but not all, AAPs in bipolar depression. Additionally and in contrast to KMAP-BP 2014 suggestions for first-line, the use of aripiprazole as combination therapy is labeled as not recommended by the updated CANMAT guidelines.14 It reflects some results that showed aripiprazole monotherapy to be not superior to placebo.28,29 However, another meta-analysis suggested that aripiprazole monotherapy could be effective for the treatment of acute depression because the combined data from two negative studies revealed a significant effect.30,31

Other findings that are shared by KMAP-BP 2014 and the other guidelines include the strict prohibition of AD monotherapy, an increasing preference for lamotrigine and AAP, and the wide recommendation of adjunctive AD use with MS or AAP.12–15,17 However, notable differences do exist between KMAP-BP 201412 and other guidelines,13–15,17 in which MS monotherapy or AAP monotherapy is recommended as the first-line strategy based on research data.32–35 Even though the use of MS and AAP monotherapy for bipolar depression is supported by higher degrees of evidence, KMAP-BP 2014 prefers the combination therapy for severe episodes of depression with or without psychotic features (Table 4). This may be because a high proportion (64%) of Korean experts who participated in KMAP-BP 2014 work at university hospitals; their primary interests may lie in treatment-resistant cases, which generally require combination therapies. Moreover, there are methodological differences between KMAP-BP 201412 and other guidelines13–15,17 (expert consensus vs evidence-based). However, polypharmaceutical approaches to psychotropic medication appear to be increasingly common in clinical practice,36 suggesting that it is difficult to apply research-based findings to real clinical fields.

**Next-step strategy**

Regardless of the clinical situation, KMAP-BP 201412 prefers adjunctive use of another medication over switching medications. Adding lamotrigine or an AAP is the preferred treatment strategy when there is insufficient response to treatment with MS alone. This strategy is also the first-line treatment for use in individuals who respond poorly to a combination of MS + AD or MS + AAP for moderate-to-severe episodes, as is the substitution of lamotrigine for an MS. Adding lamotrigine is another preferred strategy if there is inadequate response to the combination of MS + AAP.
As next-step treatments, WFSBP 2010\(^\text{17}\) recommends the optimization of first-line medications, quetiapine + carbamazepine (or lithium), modafinil + valproic acid + AD, and ECT. CANMAT 2013\(^\text{14}\) generally recommends combination therapy (such as quetiapine + SSRI, lamotrigine + lithium [or valproic acid], and adjunctive modafinil) over monotherapy for next-step intervention. Valproic acid, lamotrigine, and adjunctive lurasidone also serve as potential second-line strategies under these guidelines. In NICE 2014, adding lamotrigine is a second-line strategy.\(^\text{15}\) Recent guidelines have dropped several strategies that were recommended in earlier guidelines, such as adjunctive thyroid hormone, adding clozapine, light therapy, other psychostimulants, and calcium channel blockers\(^\text{12–15,17}\) (Table 4).

### Rapid cycling

For treating rapid-cycling patients, regardless of their current episodes, an AAP monotherapy and a combination of MS and AAP are first-line treatment strategies, as recommended by KMAP-BP 2014.\(^\text{12}\) However, the combination of lamotrigine and MS (or AAP) is potentially preferable during episodes of current depression. Adding another MS is the second-line strategy. These results are consistent with the findings of a previous study indicating that MS monotherapy has a limited effect on rapid cycling, and a combination of lithium and valproic acid is reported to be more effective than lithium or valproic acid monotherapy.\(^\text{37}\)

Valproic acid and lithium are preferred, and quetiapine, olanzapine, and aripiprazole are additional first-line agents. Since the recent accumulation of data showing that AAP treatment is also effective for rapid-cycling bipolar disorder,\(^\text{30,38–41}\) the preference for AAP alone or in combination with MS has increased in the KMAP guidelines. Clozapine and ECT are evaluated as next-step interventions for individuals with unsuccessful prior treatments.

In contrast to KMAP-BP 2014, the other guidelines do not discuss strategies for treating rapid-cycling bipolar disorder. This may be due to the fact that the notion of rapid cycling has been established only fairly recently, and there is still insufficient research dealing with this phenomenon. Direct comparison across guidelines will be possible once a more comprehensive understanding of rapid cycling is achieved (Table 5).
### Table 5 Treatment of rapid cycling across practice guidelines

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>First-line treatment</th>
<th>Next-step intervention</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>KMAP-BP 2014</td>
<td>Currently manic: MS + AAP, AAP</td>
<td>Currently manic: two MSs + AAP, change AAP or MS, ECT</td>
<td>Change AAP to CLZ or add other AAP, MS (including CBZ, ECT)</td>
</tr>
<tr>
<td></td>
<td>Currently depressed: MS + AAP, AAP, MS, or AAP + LTG</td>
<td>Currently depressed: change or add MS, MS + AAP + LTG, add AD, ECT</td>
<td></td>
</tr>
<tr>
<td>BAP 2009</td>
<td>No recommendation</td>
<td>No recommendation</td>
<td></td>
</tr>
<tr>
<td>CANMAT 2013</td>
<td>Not mentioned</td>
<td>Not mentioned</td>
<td></td>
</tr>
<tr>
<td>NICE 2014</td>
<td>Same as with other types of bipolar disorder</td>
<td>Same as with other types of bipolar disorder</td>
<td></td>
</tr>
<tr>
<td>WFSBP 2009</td>
<td>Not mentioned</td>
<td>Not mentioned</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** KMAP-BP 2014, Korean Medication Algorithm Project for Bipolar Disorder 2014; BAP 2009, The British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder 2009; CANMAT 2013, Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder 2013; NICE 2014, National Institute for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder 2014; WFSBP 2009, World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder 2009 (treatment of acute mania); MS, mood stabilizer; AAP, atypical antipsychotic; LTG, lamotrigine; ECT, electroconvulsive therapy; AD, antidepressant; CLZ, clozapine; CBZ, carbamazepine.

### Continuation and maintenance treatment

In KMAP-BP 2014, the preferred maintenance treatment strategies for recently manic bipolar I disorder are the combination of MS and AAP, MS monotherapy, or AAP monotherapy, with MS + lamotrigine and a combination therapy of two MSs recommended as second-line treatment strategies for recently manic patients. The preferred AAPs for maintenance treatment include quetiapine, aripiprazole, olanzapine, and risperidone, for use in monotherapy or in adjunctive use with MS. Ziprasidone, amisulpride, and blonanserin are recommended as strategies for next-step intervention.

If a manic episode develops during MS monotherapy, optimization of MS or adding an AAP is the preferred strategy. Quetiapine, aripiprazole, olanzapine, and risperidone are the preferred AAPs for this situation, and ziprasidone, amisulpride, and blonanserin are second-line agents. These preferences are similar to maintenance strategies with recently manic patients.

If the manic episode develops during AAP monotherapy, adding an MS is the first-line strategy. Combining two MSs, or switching from one MS to another, is offered as the next-step intervention.

In KMAP-BP 2014, the preferred maintenance strategy for recently depressed bipolar I disorder is the same as that of bipolar II disorder. The recommended first-line strategies are AAP + lamotrigine, MS + lamotrigine, MS + AAP, MS alone, AAP alone, and lamotrigine alone. However, second-line strategies are different for the two groups. In the case of bipolar I depression, two MSs or MS + AAP + lamotrigine is recommended. But for bipolar II depression, the preferred second-line strategies are AAP + MS + lamotrigine and MS + AD. The preferred first-line ADs are bupropion, escitalopram, and sertraline, with mirtazapine, fluoxetine, duloxetine, and venlafaxine serving as next-step candidates.

BAP 2009 recommends the following: if mania predominates, lithium, aripiprazole, quetiapine, valproic acid, and olanzapine are preferred, whereas if depression predominates, quetiapine and lamotrigine are first-line strategies. CANMAT 2013’s first-line recommendations are similar to those in KMAP-BP 2014. CANMAT 2013 lists lamotrigine as a first-line drug for maintenance therapy, primarily for preventing depression. The previous version of CANMAT lists aripiprazole as a first-line drug to be used primarily for preventing mania. However, given that numerous studies indicate that aripiprazole is effective in preventing both mania and depression, the updated version of the guidelines suggests aripiprazole as a first-line medication for preventing both manic and depressive episodes. CANMAT 2013 recommends long-acting injectable risperidone as a first-line strategy, either as a monotherapy or in combination with MS, based on results showing its positive effects in preventing bipolar episodes. In WFSBP 2013, aripiprazole, lamotrigine, lithium, and quetiapine are suggested as first-line drugs for preventing episodes of bipolar disorder. However, olanzapine and risperidone are next-step intervention strategies, a point on which WFSBP 2013 differs from the other guidelines. There are no published randomized controlled trials that evaluate bipolar maintenance treatment with risperidone, and some controversies about olanzapine’s depression-preventing effect exist. Although many guidelines recommend olanzapine and risperidone as first-line drugs, clinicians might wish to consider this point.

NICE 2014, the most recently published set of guidelines, recommends lithium as a first-line drug and valproic acid, olanzapine, and quetiapine as second-line medications. In addition, NICE 2014 also suggests AD, paliperidone, and ziprasidone as next-step strategies, recommendations that differ substantially from other guidelines. However,
Table 6 Continuation and maintenance treatment across practice guidelines

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>First-line treatment</th>
<th>Next-step intervention</th>
<th>Later intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>KMAP-BP 2014</td>
<td>BP-I, recently manic: MS + AAP, MS, AAP</td>
<td>BP-I, recently manic: MS + LTG, two MS</td>
<td>Recently manic and hypomanic: AAP + LTG, MS + AAP + LTG + AAP + MS + AD, LTG</td>
</tr>
<tr>
<td></td>
<td>BP-I in breakthrough mania: optimization, MS + AAP, add AAP</td>
<td>BP-I in breakthrough mania: Li or Val + other MS, change MS</td>
<td>BP-I in breakthrough mania: optimize/change MS</td>
</tr>
<tr>
<td></td>
<td>BP-II, recently hypomanic: MS, AAP, MS + AAP</td>
<td>BP-II, recently hypomanic: MS, MS + AAP + LTG</td>
<td>BP-II, recently depressed: MS + AAP + AD, MS + AD</td>
</tr>
<tr>
<td></td>
<td>BP-I and BP-II, recently depressed: AAP or MS + LTG, MS + AAP, MS, AAP, LTG</td>
<td>BP-II, recently hypomanic: AAP + LTG + MS + LTG</td>
<td>BP-II, recently depressed: MS + AAP + AD, AAP + AD, AAP + AD + LTG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If mania predominates: CBZ, PAL, Li + Val + CBZ, Li + Val + OLZ</td>
<td>Combination therapy: CLZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If depression predominates: QTP, LG</td>
<td>ASA</td>
</tr>
<tr>
<td>BAP 2009</td>
<td>If mania predominates: Li, ARP, QTP, Val, OLZ</td>
<td>If depression predominates: Li CBZ, PAL, Li + Val, Li + CBZ</td>
<td>Adjuvant therapy: CLZ, adjunctive ECT, adjunctive TP, adjunctive omega-3-fatty acid, adjunctive OXC, or adjunctive gabapentin</td>
</tr>
<tr>
<td></td>
<td>If depression predominates: QTP, LG</td>
<td>Li or Val + OLZ, Li + RIS, Li + LTG, OLZ + FX</td>
<td>Adjuvant ASA</td>
</tr>
<tr>
<td>CANMAT 2013</td>
<td>Li, LTG (limited efficacy in preventing mania), Val, OLZ, QTP, RIS LAI, ARP, adjunctive with MS: QTP, RIS LAI, ARP, ZIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NICE 2014</td>
<td>Li (mania and any episode), LTG (depression and any episode), Li (any episode), QTP (any episode)</td>
<td>Val, OLZ, QTP</td>
<td>AD (depression), PAL (mania and any episode), Val (depression), adjunctive ZIP (mania and any episode)</td>
</tr>
<tr>
<td>WFSBP 2013</td>
<td>ARP (mania and any episode), LTG (depression and any episode), Li (any episode), QTP (any episode)</td>
<td>OLZ (mania and any episode), RIS (mania and any episode)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: KMAP-BP 2014, Korean Medication Algorithm Project for Bipolar Disorder 2014; BAP 2009, The British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder 2009; CANMAT 2013, Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Patients with Bipolar Disorder 2013; CANMAT 2013, Canadian Network for Health and Clinical Excellence Clinical Guideline for Bipolar Disorder 2014; WFSBP 2013, World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Bipolar Disorder 2013 (maintenance treatment); BP-I, bipolar I disorder; MS, mood stabilizer; AAP, atypical antipsychotic; BP-II, bipolar II disorder; LTG, lamotrigine; Li, lithium; Val, valproic acid; AD, antidepressant; ARP, aripiprazole; QTP, quetiapine; OLZ, olanzapine; CBZ, carbamazepine; CLZ, clozapine; RIS LAI, risperidone long-acting injection; ZIP, ziprasidone; PAL, paliperidone; RIS, risperidone; FX, fluoxetine; ASA, asenapine; ECT, electroconvulsive therapy; TP, topiramate; OXC, oxcarbazepine.

It is worth noting that the NICE 2014 guidelines provide recommendations based on the experience and opinion of the Guideline Development Group, rather than on detailed assessments of evidence.

We found that in discussing maintenance treatments for bipolar disorder, numerous results are consistent across the various guidelines, including KMAP-BP 2014. However, despite the increased attention and research directed at bipolar II disorder, most guidelines, with the exception of KMAP-BP 2014 and CANMAT 2013, do not describe detailed therapeutic recommendations pertaining to maintenance treatment of bipolar II disorder. Also noteworthy is the increasing preference over time for aripiprazole and lamotrigine as part of a maintenance strategy, likely due to new research findings and the accumulation of clinical experience (Table 6).

**Discussion**

Although various guidelines have been offered to improve clinical practice, their enforcement has been difficult to achieve because they have different characteristics in terms of their clarity, simplicity of recommendations, reliability, and use of evidence-based medicine.50,51

In this review, we compared the recommendations of KMAP-BP 2014 with those of other widely used treatment guidelines. For the initial treatment of mania, there are no substantial differences across treatment guidelines. All guidelines recommend MS alone, or AAP alone, or MS + AAP as first-line treatment strategy for mania. However, KMAP-BP 2014 differs from other guidelines in that it does not recommend monotherapy of MS or AAP for mixed/psychotic mania. Aripiprazole, olanzapine, quetiapine, and risperidone are the first-line AAPs for manic episodes across the guidelines, with ziprasidone recommended as an additional first-line drug in some guidelines. In cases of nonresponse or incomplete response, the guidelines recommend switching to or adding another first-line agent. The KMAP-BP 2014 guidelines recommend switching from one MS or AAP to another one. Additionally, triple combinations such as lithium + two AAPs or lithium + valproic acid + AAP are suggested as next-step interventions in KMAP-BP 2014. CANMAT
2013 recommends carbamazepine as a next-step intervention. ECT and clozapine are recommended in most guidelines.

Monotherapy with MS or AAP is the first-line strategy for a mild episode of bipolar depression. In moderate-to-severe depression, MS + AAP, or MS + lamotrigine, or AAP + AD is preferred. Valproic acid, lithium, and lamotrigine are rated as first-line MSs, and quetiapine, aripiprazole, and olanzapine are rated as first-line AAPs for bipolar depression. The strict prohibition of AD monotherapy and an increasing preference for lamotrigine and AAP are found in all guidelines. However, adjunctive AD use with MS or AAP is more widely recommended. KMAP-BP 2014 prefers the adjunctive use of another medication rather than switching as the next-step strategy for depressive episodes.

AAP alone and MS + AAP are first-line treatment strategies for treating rapid cycling in KMAP-BP 2014. However, other guidelines do not discuss strategies for rapid cycling.

Among maintenance treatments, MS + AAP, MS alone, or AAP alone is the first-line strategy in KMAP-BP 2014. This is similar to other guidelines, although some of the other guidelines prefer MS, or AAP, or lamotrigine monotherapy. There is an increasing preference for aripiprazole and lamotrigine during maintenance.

There are no substantial differences between KMAP-BP 2014 and other treatment guidelines. In particular, the increased preference for AAP and lamotrigine patterns similarly in all the guidelines. However, a strong preference for combination therapy is characteristic of KMAP-BP 2014, predominantly in the treatment of dysphoric/psychotic mania and severe depression.

There may be several explanations for this. First, European guidelines tend to prefer monotherapy, but American guidelines take a more permissive stance on combination therapy. The recommendations in KMAP-BP 2014 may reflect the influence of results from frequently cited American studies. Second, it might be that many of the KMAP-BP 2014 experts are working in university hospital, where more treatment-resistant cases were treated.

While similarities between the KMAP-BP 2014 and the treatment algorithms may reflect the evidence base and consensus in some areas such as treatment of mania, areas where evidence are still sparse or lacking such as in rapid cycling, mixed mania, and treatment resistance, the guidelines often vary in their suggestions.

Limitations
KMAP-BP 2014 guideline was an expert consensus guideline, but other guidelines compared were evidence-based one. Some treatment strategies in KMAP-BP 2014 may not have been rated as first-line options despite evidence demonstrating their effectiveness. Evidence-based treatment evaluation is a systematic process that critically evaluates the scientific evidence about a particular treatment. Evidence comes from many sources, including randomized clinical trials, cohort studies, observational case studies, and retrospective studies. These good evidences make clinicians to evaluate the actual effect of a treatment on patient outcomes. However, most of these experimental data in evidence-based guidelines are derived from randomized controlled trials and may not reflect the complexity of real clinical situations, which suggests that there may be some discrepancies between the findings of randomized controlled trials and the real-world practice.

KMAP-BP 2014 has limitations as a set of expert consensus guidelines. Hence, we made efforts to compensate for these limitations by opening the public hearing at the Academic Conference of the Korean College of Neuropsychopharmacology, and by opening the results announcement and panel discussion at the Academic Conference of the Korean Society for Affective Disorders. Despite the limits of expert opinion, our current comparison shows that there are no major differences in overall treatment recommendations between KMAP-BP 2014 and other guidelines. Furthermore, the recommendations of KMAP-BP 2014 align well with current changes in the pharmacotherapy of bipolar disorder based on new evidence. However, we also found some differences between KMAP-BP 2014 and other guidelines with respect to the recommended treatments for mixed/psychotic mania and severe depression. This likely reflects the controversial nature of the results in these areas; as relevant studies accumulate, they may prompt appropriate modifications to some of the guidelines. Finally, we have reason to believe that KMAP-BP 2014 provides useful information to Korean clinicians regarding their clinical decision-making, and that the guidelines are well administered in Korean clinical practice.

Acknowledgments
This study was supported by the Korean Society for Affective Disorders and the Korean College of Neuropsychopharmacology.

Disclosure
The authors do not have any conflicts of interest relevant to the conduct of this study or preparation of the manuscript.
References


